Research programme: bacteria-based cancer therapies - T3 Pharmaceuticals
Latest Information Update: 29 Nov 2023
At a glance
- Originator T3 Pharmaceuticals
- Class Antineoplastics; Bacteria; Gene therapies; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours